Edgar Filing: FATE THERAPEUTICS INC - Form 4

FATE THER Form 4 January 12, 2	APEUTICS INC								
FORM 4UNITED STATES SECURITIES AND EX Washington, D.C. 2Check this box if no longer subject to Section 16. Form 4 or Form 5 					C. 20549 3235-028 NEFICIAL OWNERSHIP OF IES Exchange Act of 1934, g Company Act of 1935 or Section 3235-028 Number: 3235-028 Expires: 200 Estimated average burden hours per response 0.				
(Print or Type R 1. Name and Ac FATE THER	1	er Name and Ticker or Trading THERAPEUTICS INC]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O FATE T INC.;, 3535 COURT #20	ate of Earliest Transaction nth/Day/Year) 08/2016				Director 10% Owner X Officer (give title Other (specify below) below) below) Chief Development Officer				
SAN DIEGO	mendment, Da /onth/Day/Year))			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 				
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. if Transactic Code ar) (Instr. 8) Code V	4. Securi onAcquirec Disposec (Instr. 3,	ties l (A) c l of (D	r)) 5) Price	quired, Disposed of 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	-
Stock	01/08/2016		А	3,803 (1)	А	\$0	43,863	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 2 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative **Expiration Date Underlying Securities** (Month/Day/Year) (Instr. 3 and 4) Security or Exercise any Code Securities Price of (Month/Day/Year) (Instr. 8) Acquired (A) or (Instr. 3) Derivative Disposed of (D) Security (Instr. 3, 4, and 5) Amount or Date Expiration Title Number of Date Exercisable (D) Code V (A) Shares Stock Option Common (2) 01/07/2026 \$ 2.9 01/08/2016 148,800 148,800 Α Stock (right to buy) **Reporting Owners** Relationships **Reporting Owner Name / Address** Director 10% Owner Officer Other FATE THERAPEUTICS INC C/O FATE THERAPEUTICS, INC.; Chief Development Officer 3535 GENERAL ATOMICS COURT #200 SAN DIEGO, CA 92121 Signatures

/s/ Cindy R. Tahl, as Attorney-in-Fact

01/12/2016

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares issued pursuant to the Company's 2013 Stock Option and Incentive Plan as a portion of a bonus earned by the reporting person for the fiscal year ended December 31, 2015.
- (2) The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020.
- (3) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Edgar Filing: FATE THERAPEUTICS INC - Form 4